Abstract 1290TiP
Background
Adjuvant (adj) or neoadjuvant (neoadj) immunotherapy has been recently approved for the treatment of resectable early stage Non-Small Cell Lung Cancer (NSCLC), and further advances are needed. The combination of neoadj Durvalumab (D), an anti-PD-L1, combined with chemotherapy (CT) and adj D (AEGEAN) in early-stage NSCLC has recently demonstrated promising safety and efficacy. CD39 is an extracellular ectonucleotidase highly expressed in the tumor microenvironment (TME) that, sequentially with CD73, contributes to the production of adenosine (Ado), via hydrolysis of Ado triphosphate (ATP). IPH5201 is a blocking anti-CD39 monoclonal antibody that may promote antitumor immunity by accumulating immunostimulatory ATP released by CT-treated tumor cells and reducing immunosuppressive Ado levels in the TME. Moreover, IPH5201 improved the efficacy of CT+D in preclinical models. In a phase 1, IPH5201 + D was well tolerated and pharmacodynamically active.
Trial design
MATISSE is a phase II multicenter (France, Poland, Greece, Hungary, USA), single arm study (NCT05742607) sponsored by Innate Pharma, evaluating IPH5201 + D + CT in treatment-naive pts with resectable (stage II to IIIA) NSCLC. Up to 70 pts will receive neoadj IPH5201 + D in addition to platinum-doublet CT for 4 cycles followed by surgery within 40 days. Pts will thereafter receive adj IPH5201+D every 4 weeks for up to 12 cycles post-surgery or until recurrence or unacceptable toxicity. The primary objectives are to assess antitumor activity of neoadj treatment based on pathological complete response (pCR) and safety. The secondary objectives are to assess efficacy in terms of event free survival, disease free survival, feasibility of receiving the planned surgery, major pathological response, objective response rate, overall survival, pharmacokinetics and immunogenicity. Assessment of exploratory biomarkers is also planned. A Safety Review Committee will conduct evaluations on an ongoing basis and two interim analyses will be performed.
Clinical trial identification
IND:162253; NCT05742607; EudraCT: 2022-001903-42.
Editorial acknowledgement
Legal entity responsible for the study
Innate Pharma.
Funding
Innate Pharma.
Disclosure
F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, AbbVie, Acea, Amgen, Eisai, Ignyta; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd., Innate Pharma, Mirati. O. Mercier: Financial Interests, Personal, Advisory Board, Board on surgical oncology (lung cancer): AstraZeneca; Financial Interests, Personal, Advisory Board, Board for CTEPH (non cancer related): MSD; Financial Interests, Institutional, Funding, Paceport Study investigator (non cancer related) Study on pulmonary hemodynamics: Edwards Lifesciences. A. Łowczak, S. Mandziuk, J. Kuzdzal, A. Dasgupta: Non-Financial Interests, Institutional, Principal Investigator: Innate. A. Koutras: Financial Interests, Personal, Advisory Board: Pierre Fabre, AstraZeneca, Gilead, Pfizer, Genesis, MSD, BMS; Financial Interests, Personal, Invited Speaker: Sanofi, Gilead; Financial Interests, Personal, Other, Travel, Accommodations: Rafarm, Lilly, Ipsen, Gilead, Pfizer; Financial Interests, Institutional, Funding: Lilly, Pfizer, Merck; Financial Interests, Institutional, Research Grant: AstraZeneca, Pierre Fabre, BMS, Demo, Faran, Amgen, Roche, Ipsen, Galenica, Win Medica. A.J. Leyco, P. Andre, C.L. Paturel, A. Boyer Chammard: Financial Interests, Institutional, Full or part-time Employment: Innate. R. Mager, P.G. Fraenkel: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca.
Resources from the same session
1301P - A prognostic clinical and circulating biomarker model to identify futile chemo-radiotherapy (CRT) in stage III NSCLC
Presenter: Rianne Vaes
Session: Poster session 04
1302P - Treatment outcomes and safety of durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in Thai populations: A real-world, multi-center observational study
Presenter: Piyada Sitthideatphaiboon
Session: Poster session 04
1303P - Immune-modulating effects on tumor draining lymph nodes following neoadjuvant chemoradiotherapy combined with immunotherapy in patients with T3-4N0-1 NSCLC
Presenter: Ezgi Ulas
Session: Poster session 04
1304P - A structured multidisciplinary approach for diagnosing immune-related pneumonitis in patients undergoing adjuvant durvalumab for stage III non-small cell lung cancer
Presenter: Illaa Smesseim
Session: Poster session 04
1305P - Importance of the resected lung tumor specimen in patients with locally advanced and metastatic non-small cell lung cancer undergoing prior targeted therapy
Presenter: Jeong Uk Lim
Session: Poster session 04
1307P - The Biocartis Idylla GeneFusion Assay (RUO) for lung cancer testing: The experience of testing over 5000 tumours in routine practice
Presenter: Lee Robertson
Session: Poster session 04
1308P - Diameter threshold for lung nodules at low-dose CT screening: Chinese population screening experience
Presenter: YE WENJUN
Session: Poster session 04
1309P - Immune exhaustion in tumor-free lymph nodes of non-small cell lung cancer (NSCLC) patients is associated with performance status and survival
Presenter: Laura Sellmer
Session: Poster session 04
1310P - Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes
Presenter: Xiwen Liu
Session: Poster session 04
1311P - Understanding the basis for intrinsic resistance to KRASG12C inhibitors
Presenter: Alba Santos Ramos
Session: Poster session 04